Japan and India -DAIICHI SANKYO AND RANBAXY TO INTEGRATE NEW DRUG RESEARCH in low molecular weight infectious disease treatments Daiichi Sankyo Company Limited (“Daiichi Sankyo”) and Ranbaxy Laboratories Limited (“Ranbaxy”) have announced that Ranbaxy’s New Drug Discovery Research (“NDDR”) has been transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global Research and Development (R&D) to create promising new drugs, especially in the area of low molecular weight infectious and inflammatory disease treatments. The new organization, Daiichi Sankyo Life Science Research Center in India (“RCI”), based in Gurgaon, will play a key role in the Group’s global Drug Discovery Research. RCI will also continue to support the programs of dengue and tuberculosis that NDDR was working on in alliance with the Department of Biotechnology, Ministry of Science and Technology, Government of India.
Nepal -
Multiple drug resistance in bacterial isolates from liquid wastes generated in central hospitals of NepalHongkong -The Centre for Health Protection (CHP) of the Department of Health today (June 24) called on the public to be
vigilant against infection by community-associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA), a drug resistant bacterium.
The appeal was made following the CHP's investigation into a confirmed case of invasive CA-MRSA involving a 38-year-old man living in Kowloon City.
No comments:
Post a Comment